A Commercial Dynorphin Product Was Contaminated and Gave Misleading Results
A commercially purchased dynorphin preparation raised calcium levels in pituitary cells — but the effect was from LHRH contamination, not dynorphin itself.
Quick Facts
What This Study Found
A commercially purchased synthetic dynorphin A-(1-13) raised cytosolic calcium in rat pituitary cells. However, this effect was NOT caused by dynorphin itself.
When the same preparation was purified by HPLC, the calcium-raising effect disappeared. HPLC combined with LHRH radioimmunoassay revealed contamination with a LHRH-like compound (luteinizing hormone-releasing hormone).
The LHRH antagonist blocked the calcium effect, confirming the contamination. Pure dynorphin A-(1-13), dynorphin A-(2-13), leu-enkephalin, beta-endorphin, morphine, and U50,488H all had zero effect on pituitary calcium.
LHRH itself raised calcium by about 50 nM, which was blocked by the LHRH antagonist.
Key Numbers
How They Did This
Rat anterior pituitary cells were loaded with fura-2 (a fluorescent calcium indicator). Calcium changes were measured in response to opioid peptides. HPLC purification separated dynorphin from contaminants. LHRH radioimmunoassay and receptor binding studies identified the contaminant.
Why This Research Matters
This is a critical warning about peptide purity. A commercially available research-grade peptide was contaminated enough to produce completely false results. Any study using unpurified commercial peptides could be reporting artifact effects. This finding has implications for both research integrity and for consumers of research peptides.
The Bigger Picture
This cautionary study shows that commercial peptide preparations can contain biologically active contaminants that produce misleading results. It underscores the need for rigorous quality control in peptide research and therapeutic use.
What This Study Doesn't Tell Us
Only one commercial preparation was tested. The specific contaminant was not fully identified (described as LHRH-like). The study focused on calcium effects; other contamination effects were not tested.
Questions This Raises
- ?How common is peptide contamination in commercial preparations?
- ?Should all commercial peptides be HPLC-verified before use?
Trust & Context
- Key Stat:
- LHRH contamination In a commercial synthetic dynorphin preparation — produced entirely misleading results
- Evidence Grade:
- Preliminary but critically important quality control study with rigorous methodology.
- Study Age:
- Published in 1988 — an enduring cautionary tale for peptide quality control.
- Original Title:
- Opioids and cytosolic calcium in rat anterior pituitary: dynorphin preparation showed LHRH-like action due to contamination.
- Published In:
- Experientia, 44(11-12), 1003-5 (1988)
- Authors:
- Knepel, W, Schöfl, C, Wesemeyer, G, Götz, D M
- Database ID:
- RPEP-00078
Evidence Hierarchy
Frequently Asked Questions
How was the contamination detected?
The researchers noticed the calcium effect was blocked by an LHRH receptor antagonist, not an opioid antagonist. HPLC analysis then confirmed LHRH peptide was present in the dynorphin preparation.
Does this affect therapeutic peptides?
Therapeutic-grade peptides undergo much stricter quality control than research-grade. However, this study highlights why purity testing is critical for any peptide used in research or medicine.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00078APA
Knepel, W; Schöfl, C; Wesemeyer, G; Götz, D M. (1988). Opioids and cytosolic calcium in rat anterior pituitary: dynorphin preparation showed LHRH-like action due to contamination.. Experientia, 44(11-12), 1003-5.
MLA
Knepel, W, et al. "Opioids and cytosolic calcium in rat anterior pituitary: dynorphin preparation showed LHRH-like action due to contamination.." Experientia, 1988.
RethinkPeptides
RethinkPeptides Research Database. "Opioids and cytosolic calcium in rat anterior pituitary: dyn..." RPEP-00078. Retrieved from https://rethinkpeptides.com/research/knepel-1988-opioids-and-cytosolic-calcium
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.